MedPath

Cholangioscopy in intraductal staging of resectable extrahepatic CholangioCarcinoma

Recruiting
Conditions
bile duct cancer
cholangiocarcinoma
10018008
10019815
Registration Number
NL-OMON52099
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
25
Inclusion Criteria

- Patients with resectable EC undergoing ERCP to achieve pre-operative biliary
decompression of the FRL
- (Suspicion of) EC is based on clinical assessment and imaging results
(MRI/MRCP and CT), histological confirmation is not obligatory.
- Resectability of the tumor was evaluated at the regional multidisciplinary
team meeting
- Biliary stenosis located distally, or perihilar according to Bismuth
classification based on imaging results (MRI/MRCP/CT)
- Informed consent
- Age >= 18 years

Exclusion Criteria

• Intrahepatic cholangiocarcinoma
• Irresectable tumor
• Previous treatment with a biliary plastic endoprothesis or self-expandable
metal stent (SEMS)
• Previous treatment with a percutaneous transhepatic biliary drain
• Patients with expected very limited survival (< 6 weeks)
• Biliary obstruction not amenable to endoscopic drainage, for example due to
altered anatomy

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Technical feasibility to perform cholangioscopy in EC, defined as the technical<br /><br>success to advance the Spyglass DS II cholangioscope through the malignant<br /><br>stricture into the intended (segmental) bile duct system(s), to assess ductal<br /><br>tumor borders optically and to obtain mapping biopsies of the locations of<br /><br>interest depending on the predetermined resection lines. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>1. Overall diagnostic value of optical cholangioscopic assessment combined with<br /><br>biopsies of bile duct locations at interest outside the predetermined resection<br /><br>lines.<br /><br><br /><br>2. Diagnostic value of optical cholangioscopic assessment or biopsies alone.<br /><br><br /><br>3.Adverse outcomes after cholangioscopy defined by any cholangioscopy-related<br /><br>AE or mortality within 30 days. The AE will be recorded according the ASGE<br /><br>lexicon.</p><br>
© Copyright 2025. All Rights Reserved by MedPath